| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 136 | 2022 | 15694 | 3.530 |
Why?
|
| Mastectomy | 31 | 2019 | 1534 | 2.630 |
Why?
|
| Mastectomy, Segmental | 34 | 2021 | 1026 | 2.500 |
Why?
|
| Carcinoma, Ductal, Breast | 29 | 2018 | 1216 | 2.270 |
Why?
|
| Sentinel Lymph Node Biopsy | 37 | 2017 | 1415 | 2.210 |
Why?
|
| Inflammatory Breast Neoplasms | 7 | 2018 | 509 | 1.760 |
Why?
|
| Carcinoma, Lobular | 23 | 2018 | 611 | 1.610 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 18 | 2019 | 674 | 1.360 |
Why?
|
| Nipples | 6 | 2013 | 132 | 1.160 |
Why?
|
| Lymphatic Metastasis | 39 | 2020 | 4844 | 1.020 |
Why?
|
| Lymph Nodes | 20 | 2019 | 2967 | 0.980 |
Why?
|
| Neoplasm Recurrence, Local | 38 | 2018 | 10035 | 0.850 |
Why?
|
| Databases, Factual | 10 | 2019 | 2218 | 0.840 |
Why?
|
| Neoplasm Staging | 57 | 2019 | 13658 | 0.800 |
Why?
|
| Axilla | 22 | 2017 | 902 | 0.750 |
Why?
|
| Mammaplasty | 7 | 2018 | 780 | 0.700 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 6 | 2012 | 115 | 0.680 |
Why?
|
| Radiotherapy, Adjuvant | 12 | 2019 | 2231 | 0.650 |
Why?
|
| Chemotherapy, Adjuvant | 18 | 2021 | 3890 | 0.640 |
Why?
|
| Aged | 99 | 2021 | 70117 | 0.640 |
Why?
|
| Female | 142 | 2022 | 141928 | 0.620 |
Why?
|
| Middle Aged | 108 | 2019 | 86204 | 0.600 |
Why?
|
| Lymph Node Excision | 15 | 2019 | 1959 | 0.570 |
Why?
|
| Adult | 97 | 2019 | 77950 | 0.540 |
Why?
|
| Aged, 80 and over | 59 | 2020 | 29902 | 0.530 |
Why?
|
| Brachytherapy | 4 | 2018 | 977 | 0.520 |
Why?
|
| Healthcare Disparities | 3 | 2016 | 598 | 0.520 |
Why?
|
| Aftercare | 1 | 2016 | 259 | 0.500 |
Why?
|
| Combined Modality Therapy | 23 | 2021 | 8865 | 0.500 |
Why?
|
| Quality of Life | 5 | 2022 | 4532 | 0.460 |
Why?
|
| Receptors, Estrogen | 10 | 2021 | 2086 | 0.460 |
Why?
|
| Humans | 146 | 2022 | 261506 | 0.450 |
Why?
|
| Carcinoma in Situ | 7 | 2008 | 487 | 0.450 |
Why?
|
| Mammography | 6 | 2019 | 1010 | 0.440 |
Why?
|
| Population Surveillance | 1 | 2016 | 627 | 0.440 |
Why?
|
| Neoadjuvant Therapy | 19 | 2018 | 4975 | 0.430 |
Why?
|
| Sentinel Lymph Node | 4 | 2019 | 216 | 0.420 |
Why?
|
| Carcinoma | 8 | 2017 | 2578 | 0.420 |
Why?
|
| Catheterization | 2 | 2014 | 410 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2017 | 1303 | 0.410 |
Why?
|
| Mastectomy, Simple | 4 | 2017 | 58 | 0.410 |
Why?
|
| Neoplasm Metastasis | 8 | 2018 | 5112 | 0.410 |
Why?
|
| Preoperative Period | 2 | 2017 | 344 | 0.390 |
Why?
|
| Breathing Exercises | 1 | 2010 | 21 | 0.380 |
Why?
|
| Radiation Oncology | 1 | 2015 | 529 | 0.370 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 450 | 0.370 |
Why?
|
| Prognosis | 38 | 2018 | 21713 | 0.370 |
Why?
|
| Survival Rate | 21 | 2022 | 12221 | 0.360 |
Why?
|
| Societies, Medical | 2 | 2015 | 1335 | 0.360 |
Why?
|
| Patient Satisfaction | 2 | 2011 | 915 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2018 | 15862 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 2403 | 0.330 |
Why?
|
| Radiotherapy | 7 | 2017 | 1824 | 0.330 |
Why?
|
| Retrospective Studies | 48 | 2020 | 37905 | 0.320 |
Why?
|
| Disease-Free Survival | 21 | 2018 | 10001 | 0.310 |
Why?
|
| Paget's Disease, Mammary | 2 | 2005 | 41 | 0.310 |
Why?
|
| Guideline Adherence | 3 | 2017 | 636 | 0.310 |
Why?
|
| Follow-Up Studies | 23 | 2018 | 14889 | 0.290 |
Why?
|
| Radiopharmaceuticals | 3 | 2009 | 1301 | 0.290 |
Why?
|
| Treatment Outcome | 32 | 2017 | 32848 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 18 | 2015 | 3981 | 0.280 |
Why?
|
| Widowhood | 1 | 2005 | 8 | 0.270 |
Why?
|
| Tumor Burden | 3 | 2016 | 1987 | 0.270 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2019 | 840 | 0.270 |
Why?
|
| Patient Selection | 3 | 2010 | 2055 | 0.260 |
Why?
|
| Prospective Studies | 23 | 2018 | 12873 | 0.260 |
Why?
|
| Feasibility Studies | 10 | 2017 | 2292 | 0.260 |
Why?
|
| Rosaniline Dyes | 4 | 2017 | 108 | 0.250 |
Why?
|
| Radionuclide Imaging | 7 | 2009 | 660 | 0.250 |
Why?
|
| Carcinoma, Ductal | 1 | 2006 | 145 | 0.250 |
Why?
|
| Proportional Hazards Models | 8 | 2022 | 4988 | 0.240 |
Why?
|
| Breast Diseases | 3 | 2019 | 201 | 0.240 |
Why?
|
| Aromatase Inhibitors | 3 | 2017 | 305 | 0.230 |
Why?
|
| Decision Making | 7 | 2016 | 1287 | 0.230 |
Why?
|
| Ultrasonography, Mammary | 6 | 2019 | 380 | 0.220 |
Why?
|
| Carcinoma, Papillary | 2 | 2006 | 584 | 0.220 |
Why?
|
| Neoplasm, Residual | 8 | 2016 | 1656 | 0.220 |
Why?
|
| Young Adult | 21 | 2018 | 21445 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6207 | 0.210 |
Why?
|
| Postoperative Complications | 3 | 2014 | 5542 | 0.210 |
Why?
|
| False Negative Reactions | 5 | 2017 | 275 | 0.200 |
Why?
|
| Preoperative Care | 6 | 2017 | 1529 | 0.190 |
Why?
|
| Intraoperative Period | 4 | 2015 | 246 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2011 | 607 | 0.180 |
Why?
|
| Registries | 3 | 2018 | 2170 | 0.170 |
Why?
|
| Logistic Models | 7 | 2019 | 3441 | 0.170 |
Why?
|
| Multivariate Analysis | 7 | 2019 | 4298 | 0.170 |
Why?
|
| Cosmetics | 1 | 2018 | 17 | 0.170 |
Why?
|
| Time Factors | 12 | 2019 | 12926 | 0.160 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 63 | 0.160 |
Why?
|
| Survival Analysis | 12 | 2013 | 9180 | 0.150 |
Why?
|
| Trastuzumab | 3 | 2015 | 696 | 0.150 |
Why?
|
| Ki-67 Antigen | 2 | 2017 | 666 | 0.150 |
Why?
|
| Age Factors | 9 | 2019 | 5377 | 0.140 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2017 | 69 | 0.140 |
Why?
|
| Antineoplastic Agents | 9 | 2017 | 14289 | 0.140 |
Why?
|
| Injections | 2 | 2009 | 285 | 0.140 |
Why?
|
| Yoga | 1 | 2017 | 78 | 0.140 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2016 | 23 | 0.140 |
Why?
|
| Capecitabine | 1 | 2017 | 388 | 0.140 |
Why?
|
| United States | 6 | 2017 | 15433 | 0.130 |
Why?
|
| Radiotherapy Dosage | 4 | 2018 | 3842 | 0.130 |
Why?
|
| Breast Neoplasms, Male | 2 | 2006 | 229 | 0.120 |
Why?
|
| Surgical Oncology | 1 | 2017 | 190 | 0.120 |
Why?
|
| Fatigue | 2 | 2018 | 1239 | 0.120 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 2518 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 348 | 0.120 |
Why?
|
| Regression Analysis | 2 | 2015 | 1546 | 0.120 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2013 | 14 | 0.120 |
Why?
|
| Nomograms | 2 | 2016 | 313 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 1225 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2014 | 185 | 0.110 |
Why?
|
| Anaphylaxis | 2 | 2005 | 119 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2014 | 234 | 0.110 |
Why?
|
| Publishing | 1 | 2015 | 220 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2015 | 195 | 0.110 |
Why?
|
| Disease Progression | 4 | 2011 | 6682 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 2013 | 87 | 0.110 |
Why?
|
| Aromatase | 1 | 2012 | 56 | 0.110 |
Why?
|
| Lymphoscintigraphy | 1 | 2012 | 35 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2007 | 436 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 7702 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2017 | 621 | 0.100 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 4892 | 0.100 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 992 | 0.100 |
Why?
|
| Mortality | 1 | 2014 | 343 | 0.100 |
Why?
|
| Risk Factors | 11 | 2014 | 17523 | 0.100 |
Why?
|
| Consensus | 1 | 2015 | 978 | 0.100 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 6009 | 0.100 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 137 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2013 | 191 | 0.100 |
Why?
|
| Cryopreservation | 1 | 2011 | 175 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2017 | 1299 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2018 | 1411 | 0.100 |
Why?
|
| Breast | 4 | 2019 | 1344 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2011 | 392 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2017 | 1215 | 0.090 |
Why?
|
| Proteome | 1 | 2014 | 561 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 227 | 0.090 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2010 | 70 | 0.090 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 106 | 0.090 |
Why?
|
| Drainage | 1 | 2012 | 416 | 0.090 |
Why?
|
| Specimen Handling | 1 | 2011 | 299 | 0.090 |
Why?
|
| Organ Sparing Treatments | 1 | 2011 | 277 | 0.090 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 918 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 1586 | 0.090 |
Why?
|
| Genes, erbB-2 | 1 | 2010 | 229 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2010 | 161 | 0.090 |
Why?
|
| Lymphatic Vessels | 1 | 2010 | 143 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 771 | 0.080 |
Why?
|
| Cytological Techniques | 1 | 2009 | 74 | 0.080 |
Why?
|
| Frozen Sections | 1 | 2009 | 105 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2015 | 2576 | 0.080 |
Why?
|
| Androstadienes | 3 | 2017 | 165 | 0.080 |
Why?
|
| Probability | 3 | 2004 | 866 | 0.080 |
Why?
|
| Keratins | 1 | 2009 | 330 | 0.080 |
Why?
|
| Biopsy, Needle | 4 | 2004 | 1363 | 0.080 |
Why?
|
| Ultrasonography | 3 | 2017 | 1863 | 0.080 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2014 | 716 | 0.080 |
Why?
|
| Students, Medical | 1 | 2013 | 399 | 0.080 |
Why?
|
| Incidence | 7 | 2013 | 5673 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2010 | 222 | 0.080 |
Why?
|
| Seroma | 2 | 2018 | 79 | 0.080 |
Why?
|
| Catheter Ablation | 2 | 2004 | 620 | 0.080 |
Why?
|
| SEER Program | 2 | 2008 | 1000 | 0.080 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2007 | 690 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2104 | 0.070 |
Why?
|
| Radiometry | 1 | 2013 | 980 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1960 | 0.070 |
Why?
|
| Propensity Score | 2 | 2020 | 750 | 0.070 |
Why?
|
| Self Report | 1 | 2010 | 756 | 0.070 |
Why?
|
| Biology | 1 | 2007 | 75 | 0.070 |
Why?
|
| Receptors, Progesterone | 3 | 2019 | 1392 | 0.070 |
Why?
|
| Texas | 4 | 2013 | 6311 | 0.070 |
Why?
|
| Fluorouracil | 4 | 2017 | 1944 | 0.070 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2006 | 112 | 0.070 |
Why?
|
| Doxorubicin | 5 | 2017 | 3005 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2007 | 176 | 0.070 |
Why?
|
| Histamine H1 Antagonists | 1 | 2005 | 25 | 0.070 |
Why?
|
| Adenocarcinoma | 3 | 2011 | 7789 | 0.070 |
Why?
|
| Embolism | 1 | 2006 | 59 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2010 | 4971 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 1742 | 0.060 |
Why?
|
| Triazoles | 3 | 2017 | 617 | 0.060 |
Why?
|
| Nitriles | 3 | 2017 | 906 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2015 | 2370 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 4557 | 0.060 |
Why?
|
| Medical Oncology | 1 | 2013 | 1423 | 0.060 |
Why?
|
| Observer Variation | 1 | 2006 | 671 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2012 | 2203 | 0.060 |
Why?
|
| Physical Examination | 1 | 2006 | 299 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 435 | 0.060 |
Why?
|
| Risk Assessment | 5 | 2017 | 6869 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 1869 | 0.060 |
Why?
|
| Cyclophosphamide | 4 | 2017 | 3001 | 0.060 |
Why?
|
| Tamoxifen | 2 | 2005 | 876 | 0.060 |
Why?
|
| Medicare | 1 | 2008 | 860 | 0.060 |
Why?
|
| Bodily Secretions | 1 | 2003 | 12 | 0.060 |
Why?
|
| Epirubicin | 2 | 2017 | 157 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2005 | 875 | 0.060 |
Why?
|
| Age Distribution | 1 | 2004 | 698 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2006 | 739 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2007 | 622 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 4367 | 0.050 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 384 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2006 | 551 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 672 | 0.050 |
Why?
|
| Biomarkers, Tumor | 4 | 2015 | 10331 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 629 | 0.050 |
Why?
|
| Fibrosis | 2 | 2018 | 793 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2010 | 1323 | 0.050 |
Why?
|
| Thoracic Wall | 1 | 2003 | 183 | 0.050 |
Why?
|
| Cancer Care Facilities | 2 | 2017 | 884 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2009 | 1350 | 0.050 |
Why?
|
| Obesity | 1 | 2012 | 2884 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 1058 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2015 | 9244 | 0.040 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 11538 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2006 | 980 | 0.040 |
Why?
|
| Income | 1 | 2019 | 222 | 0.040 |
Why?
|
| Leukopenia | 1 | 2018 | 151 | 0.040 |
Why?
|
| Muscle Stretching Exercises | 1 | 2017 | 17 | 0.040 |
Why?
|
| Alopecia | 1 | 2018 | 126 | 0.040 |
Why?
|
| Medical Records | 2 | 2013 | 415 | 0.040 |
Why?
|
| Actigraphy | 1 | 2017 | 54 | 0.040 |
Why?
|
| Technetium | 1 | 2017 | 77 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 85 | 0.040 |
Why?
|
| Male | 7 | 2020 | 123000 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2006 | 2307 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2017 | 79 | 0.040 |
Why?
|
| Splenectomy | 1 | 1997 | 158 | 0.040 |
Why?
|
| Edema | 1 | 2018 | 267 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2017 | 162 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 348 | 0.040 |
Why?
|
| Palliative Care | 1 | 2007 | 2037 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2017 | 430 | 0.030 |
Why?
|
| Supine Position | 1 | 2015 | 46 | 0.030 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2015 | 49 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2016 | 285 | 0.030 |
Why?
|
| Algorithms | 1 | 2006 | 3890 | 0.030 |
Why?
|
| Sleep | 1 | 2017 | 413 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 2352 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2014 | 256 | 0.030 |
Why?
|
| Blast Crisis | 1 | 1997 | 557 | 0.030 |
Why?
|
| Risk | 2 | 2011 | 1972 | 0.030 |
Why?
|
| Counseling | 1 | 2016 | 381 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2017 | 6100 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.030 |
Why?
|
| Social Class | 1 | 2015 | 310 | 0.030 |
Why?
|
| Tissue Expansion Devices | 1 | 2013 | 62 | 0.030 |
Why?
|
| Disease Management | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Trisomy | 1 | 2014 | 231 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 524 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 612 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2015 | 256 | 0.030 |
Why?
|
| Recurrence | 2 | 2012 | 4758 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2315 | 0.030 |
Why?
|
| Comprehension | 1 | 2013 | 120 | 0.030 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2012 | 43 | 0.030 |
Why?
|
| Karyotyping | 1 | 2014 | 1022 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2016 | 667 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2013 | 202 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2015 | 5687 | 0.030 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2012 | 142 | 0.030 |
Why?
|
| Freeze Drying | 1 | 2011 | 30 | 0.030 |
Why?
|
| Necrosis | 1 | 2013 | 580 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2012 | 233 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3472 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 362 | 0.020 |
Why?
|
| Health Services for the Aged | 1 | 2010 | 50 | 0.020 |
Why?
|
| Causality | 1 | 2010 | 178 | 0.020 |
Why?
|
| Biopsy | 2 | 2011 | 3443 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 3251 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2010 | 234 | 0.020 |
Why?
|
| Pain | 1 | 2018 | 1658 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 5395 | 0.020 |
Why?
|
| Cellulitis | 1 | 2010 | 72 | 0.020 |
Why?
|
| Adolescent | 4 | 2015 | 31252 | 0.020 |
Why?
|
| Postmenopause | 1 | 2011 | 378 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 761 | 0.020 |
Why?
|
| Remission Induction | 1 | 2015 | 3569 | 0.020 |
Why?
|
| Exercise | 1 | 2016 | 1183 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2010 | 275 | 0.020 |
Why?
|
| Diet | 1 | 2016 | 1440 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 2232 | 0.020 |
Why?
|
| Hematoma | 1 | 2010 | 160 | 0.020 |
Why?
|
| Exons | 1 | 2012 | 1328 | 0.020 |
Why?
|
| Breast Implants | 1 | 2013 | 391 | 0.020 |
Why?
|
| Abscess | 1 | 2010 | 177 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2010 | 259 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 226 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1859 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 4654 | 0.020 |
Why?
|
| Curriculum | 1 | 2013 | 860 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2009 | 429 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 1678 | 0.020 |
Why?
|
| Lymphedema | 1 | 2010 | 239 | 0.020 |
Why?
|
| Calcinosis | 1 | 2010 | 423 | 0.020 |
Why?
|
| Exome | 1 | 2012 | 1239 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 2803 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2007 | 205 | 0.020 |
Why?
|
| Early Ambulation | 1 | 2006 | 22 | 0.020 |
Why?
|
| Bandages | 1 | 2006 | 71 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1997 | 2527 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2006 | 184 | 0.020 |
Why?
|
| Mutation | 2 | 2017 | 15179 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2006 | 149 | 0.020 |
Why?
|
| Reoperation | 1 | 2009 | 1382 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2006 | 557 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 1872 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2004 | 58 | 0.020 |
Why?
|
| Tissue Expansion | 1 | 2004 | 71 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2012 | 2086 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 2003 | 52 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 467 | 0.010 |
Why?
|
| Contraindications | 1 | 2002 | 150 | 0.010 |
Why?
|
| ROC Curve | 1 | 2006 | 1183 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1362 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2003 | 297 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 1099 | 0.010 |
Why?
|
| Patient Participation | 1 | 2004 | 446 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 7551 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 5159 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 1904 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2002 | 429 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2006 | 1996 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 2594 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 792 | 0.010 |
Why?
|
| Surgical Flaps | 1 | 2004 | 927 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2002 | 1046 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 5539 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 7573 | 0.010 |
Why?
|
| Platelet Count | 1 | 1997 | 490 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2014 | 11965 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2011 | 8873 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 5437 | 0.010 |
Why?
|
| Spleen | 1 | 1997 | 676 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1997 | 583 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 4744 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 4320 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 7548 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1997 | 846 | 0.010 |
Why?
|
| Child | 2 | 2006 | 29154 | 0.010 |
Why?
|
| Animals | 1 | 2008 | 59536 | 0.000 |
Why?
|